Over the past few years, the general population has witnessed an increase in the number of cancer survivors. The surge is a result of the expansion of cancer services, screening efforts, and breakthrough cancer research. Furthermore, cancer treatments centers are now better equipped. A report from the Surveillance, Epidemiology and End Results program show remarkable statistics of the number of cancer survivors’ population. The results of the extensive research show an increase to over fifteen million in 2016. This is almost four times the number just three decades ago.
However, we would not be talking about such improvement without the helping hand of scientific research. The brains behind fighting cancer are overlooked while they toil to find a cure for this menace. One such character who is outstanding is Eric Lefkofsky. The co-founder of Tempus is spearheading the lead in developing the next generation technology to modernize cancer treatment. The health-startups help the physician to provide the right prescription for their cancer patients.
The 48-year old is the head of Tempus, the company battling cancer. He attributes his drive to fighting cancer to the experience of a close relative undergoing cancer treatment. He combines his efforts with several scientists in the field, while also collaborating with hospitals on advancements in cancer treatment. Through their state-of-the-art facilities, they help identify the genomic data of a patient providing their data science. The information is critical in picking the correct clinical care for the patient.
Additionally, Eric is an avid philanthropist towards cancer research and development. His foundation regularly donates to cancer research institutions and universities. This shows his actual goal of investing in tackling cancer on behalf of humanity. He argues that medical discoveries should be more critical, and advanced health infrastructure will be the key to precision medicine. As his efforts begin to bear fruit, Eric believes big data as a tool that is somewhat underutilized even though it will be one way of moving forward. With the number of cancer survivors increasing, understanding nature of cancer is a vital aspect in determining the success of the clinical trials.
To Learn More Click Here